Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFDAY7)

Drug Name

LY3214996 Drug Info

Synonyms

JNPRPMBJODOFEC-UHFFFAOYSA-N; 1951483-29-6; GTPL9975; SCHEMBL17837273; MolPort-046-033-624; EX-A2560; BCP19982; CS-6974; HY-101494; LY 3214996; 6,6-dimethyl-2-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5-(2-morpholin-4-ylethyl)thieno[2,3-c]pyrrol-4-one; 6,6-dimethyl-2-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-5-(2-morpholinoethyl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 121408882
CAS Number: CAS 1951483-29-6
TTD Drug ID: DMFDAY7

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Preclinical Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[2]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[5]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[8]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[9]
SB220025	DMSBUET	Arthritis	FA20	Terminated	[10]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	DOI: 10.1158/1538-7445.AM2015-4693
3	Clinical pipeline report, company report or official report of HaiHe Biopharma.
4	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
5	WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
6	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
7	National Cancer Institute Drug Dictionary (drug name JSI1187).
8	Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
9	Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
10	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11	Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.